{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:07:33Z","timestamp":1784092053291,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterized by asthma, eosinophilia, and multi-organ involvement. Adolescent-onset disease is uncommon, and evidence guiding biologic therapy in this population remains limited. We report the case of an 18-year-old female with a history of chronic rhinosinusitis and eosinophilic asthma who presented with worsening asthma control, arthralgia, and peripheral eosinophilia (4, 600 cells\/\u03bcL), with palpable purpura developing during hospitalization. Chest radiography was initially unremarkable, but chest computed tomography revealed peripheral ground-glass opacities and consolidations. Further workup demonstrated eosinophil-rich perivascular infiltrates with karyorrhectic debris without necrotizing vasculitis on skin biopsy, and high-titer anti-myeloperoxidase (anti-MPO) antibodies &amp;gt;200 RU\/mL on immunologic testing. The diagnosis of EGPA was established according to the 2022 ACR\/EULAR classification criteria with a total score of 10. Initial treatment with high-dose corticosteroids resulted in partial improvement, but the disease relapsed during tapering, indicating corticosteroid dependence. Benralizumab was subsequently introduced, leading to rapid eosinophil depletion, improved pulmonary function, successful corticosteroid reduction, and prompt clinical remission. At 12-month follow-up, the patient remained in complete remission, with normalized pulmonary function, no evidence of new organ involvement, and a marked decline in anti-MPO antibody titers. This case highlights the importance of considering EGPA in adolescents presenting with difficult-to-control eosinophilic asthma and systemic manifestations, and demonstrates that benralizumab can achieve stable, long-term remission with successful corticosteroid reduction even in ANCA-positive disease.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1896474","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:42:47Z","timestamp":1784090567000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Benralizumab-induced remission in adolescent-onset ANCA-positive eosinophilic granulomatosis with polyangiitis"],"prefix":"10.3389","volume":"17","author":[{"given":"Milica","family":"Terzic","sequence":"first","affiliation":[{"name":"Clinic for Allergology and Immunology, University Clinical Centre of Serbia","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Plavsic","sequence":"additional","affiliation":[{"name":"Clinic for Allergology and Immunology, University Clinical Centre of Serbia","place":["Belgrade, Serbia"]},{"name":"Faculty of Medicine, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Djordjevic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade","place":["Belgrade, Serbia"]},{"name":"Division of Pediatric Rheumatology, University Children\u2019s Hospital Tirsova","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos","family":"Todorovic","sequence":"additional","affiliation":[{"name":"Clinic for Allergology and Immunology, University Clinical Centre of Serbia","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bosic","sequence":"additional","affiliation":[{"name":"Institute of Pathology, School of Medicine, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snezana","family":"Arandjelovic","sequence":"additional","affiliation":[{"name":"Clinic for Allergology and Immunology, University Clinical Centre of Serbia","place":["Belgrade, Serbia"]},{"name":"Faculty of Medicine, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103219","article-title":"Eosinophilic granulomatosis with polyangiitis: a review","volume":"22","author":"White","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew029","article-title":"Eosinophilic granulomatosis with polyangiitis in childhood: retrospective experience from a tertiary referral centre in the UK","volume":"55","author":"Eleftheriou","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24089","article-title":"Eosinophilic granulomatosis with polyangiitis in children: data from the French RespiRare cohort","volume":"53","author":"Fina","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120808","article-title":"Childhood-onset eosinophilic granulomatosis with polyangiitis: a contemporary single-center cohort","volume":"40","author":"Gendelman","year":"2013","journal-title":"J Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for Eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for Eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/art.20077","article-title":"Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate","volume":"51","author":"Mahr","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep304","article-title":"Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa","volume":"48","author":"Mohammad","year":"2009","journal-title":"Rheumatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.berh.2004.11.002","article-title":"What is known about the epidemiology of the vasculitides","volume":"19","author":"Watts","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1145257","article-title":"Eosinophilic granulomatosis with polyangiitis - Advances in pathogenesis, diagnosis, and treatment","volume":"10","author":"Fijolek","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00097-2016","article-title":"Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"48","author":"Cottin","year":"2016","journal-title":"Eur Respir J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-9-200511010-00006","article-title":"Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome","volume":"143","author":"Sabl\u00e9-Fourtassou","year":"2005","journal-title":"Ann Intern Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.05.058","article-title":"Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome","volume":"131","author":"Healy","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/01.dad.0000181109.54532.c5","article-title":"Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis","volume":"27","author":"Carlson","year":"2005","journal-title":"Am J Dermatopathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.05.004","article-title":"Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients","volume":"39","author":"Zwerina","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711203372106","article-title":"Small-vessel vasculitis","volume":"337","author":"Jennette","year":"1997","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2016.09.018","article-title":"Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): a study of 157 patients","volume":"16","author":"Cottin","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202005-1628SO","article-title":"International consensus on antineutrophil cytoplasm antibodies testing in Eosinophilic granulomatosis with polyangiitis","volume":"202","author":"Moiseev","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00243-6","article-title":"Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study","volume":"5","author":"Bettiol","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224624","article-title":"Benralizumab for eosinophilic granulomatosis with polyangiitis","volume":"82","author":"Cottu","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100551","article-title":"Potential masking of new-onset or relapsed eosinophilic granulomatosis with polyangiitis during benralizumab treatment: A case series","volume":"4","author":"Ohmura","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.02.009","article-title":"Benralizumab for adolescent patients with severe, eosinophilic asthma: safety and efficacy after 3 years of treatment","volume":"148","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/pai.14092","article-title":"Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study)","volume":"35","author":"Wedner","year":"2024","journal-title":"Pediatr Allergy Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1896474\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:43:05Z","timestamp":1784090585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1896474\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1896474"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1896474","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1896474"}}